|Videos|August 30, 2021

Dr. Seth weighs in on onabotulinumtoxinA injections in patients with complex medical backgrounds

Author(s)Urology Times staff

“Botox to [the] bladder has, in some ways, changed the paradigm of treatment for [overactive bladder],” says Jai Seth, MD.

In this video, Jai Seth, MD, discusses the background and objectives of the Neurourology and Urodynamics study, “Intravesical onabotulinumtoxinA injections in patients on antiplatelet and anticoagulation therapy.” Seth is a consultant urological surgeon at St. George’s University hospital, London, UK.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Ryan Flannigan, MD, highlights phase 2 data on ST-01 for chronic scrotal content pain

ByRyan K. Flannigan, MD, FRCSC

August 14th 2026

Nima Almassi, MD, highlights long-term data on bladder preservation in MIBC

ByNima Almassi, MD

August 13th 2026

How urodynamics reshaped the goals of urologic reconstruction

BySasha Vereecken, RN

August 13th 2026

Narmina Khanmammadova, MD, discusses findings on pelvic floor therapy before HoLEP

ByNarmina Khanmammadova, MD

August 12th 2026

Jessica Yih, MD, highlights data on testosterone therapy in women

ByJessica M. Yih, MD

August 11th 2026

Latest CME

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

Focal therapy for prostate cancer frequently used outside guideline-supported groups

Registry launches to assess real-world clinical utility of ArteraAI Prostate Test

Active surveillance use for low-risk prostate cancer reaches 93% in VA System

Higher intake of ultra-processed food associated with increased prostate cancer risk

Ryan Flannigan, MD, highlights phase 2 data on ST-01 for chronic scrotal content pain